Sienna Gestion Reduces Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Sienna Gestion has reduced its stake in Intuitive Surgical, Inc. by 9.5% in the first quarter, now holding 19,383 shares worth approximately $9.3 million.
• Wall Street analysts generally maintain a positive outlook on Intuitive Surgical, with a consensus rating of "Moderate Buy" and a target price of $595.95.
• Insider selling activity is notable, with significant sales by executives including EVP Myriam Curet, who sold 4,500 shares, indicating a shift in ownership structure within the company.

Sienna Gestion reduced its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 9.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,383 shares of the medical equipment provider's stock after selling 2,027 shares during the period. Sienna Gestion's holdings in Intuitive Surgical were worth $9,331,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ISRG. Parvin Asset Management LLC purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $26,000. Chilton Capital Management LLC increased its position in shares of Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares during the last quarter. Global Financial Private Client LLC increased its position in shares of Intuitive Surgical by 253.3% in the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 38 shares during the last quarter. Elite Financial Inc. acquired a new position in shares of Intuitive Surgical in the 1st quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA acquired a new position in shares of Intuitive Surgical in the 1st quarter valued at $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of ISRG stock traded up $3.18 during mid-day trading on Friday, hitting $480.26. The stock had a trading volume of 1,436,064 shares, compared to its average volume of 2,192,612. The company's 50-day simple moving average is $508.75 and its 200-day simple moving average is $525.48. The firm has a market cap of $172.16 billion, a PE ratio of 66.98, a PEG ratio of 5.00 and a beta of 1.59. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business's revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.78 EPS. On average, analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In other news, SVP Mark Brosius sold 216 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,839 shares of company stock worth $7,896,972 in the last 90 days. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ISRG has been the subject of several research analyst reports. Royal Bank Of Canada upped their target price on shares of Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a report on Wednesday, July 23rd. UBS Group upped their target price on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Truist Financial upped their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Wells Fargo & Company upped their target price on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.